Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis

Back

ESC Premium Access

Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis

Session: Pulmonary arterial hypertension: risk stratification guides for new treatments and informed outcomes

Topic: Pulmonary Hypertension

Speaker: Doctor J. Coghlan (London, GB)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Doctor John G Coghlan

Royal Free Hospital, London (United Kingdom of Great Britain & Northern Ireland)

10 presentations

3 followers

4 more presentations in this session

Non-invasive risk prediction based on right ventricular function in patients with pulmonary arterial hypertension

Speaker: Mrs V. Qaderi (Melbourne, AU)

Inclusion of echocardiographic measure of right ventricular function in the non-invasive French pulmonary arterial hypertension risk stratification method

Speaker: Doctor C. Fauvel (Rouen, FR)

Twenty-year experience and outcomes in a national paediatric pulmonary hypertension service

Speaker: Doctor A. Constantine (Birmingham, GB)

Safety, tolerability, and pharmacokinetics (PK) of treprostinil palmitil inhalation powder (TPIP): a phase 1, randomised, double-blind, single- and multiple-dose study

Speaker: Doctor F. Ismat (Bridgewater, US)

Access the full session

Pulmonary arterial hypertension: risk stratification guides for new treatments and informed outcomes

Speakers: Doctor J. Coghlan, Mrs V. Qaderi, Doctor C. Fauvel, Doctor A. Constantine, Doctor F. Ismat

Access

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources